刘新丽, 刘芳芳, 郑屹, 沈蓓蓓, 付丽. 男性乳腺癌临床病理特征及预后分析[J]. 中国肿瘤临床, 2014, 41(23): 1521-1526. DOI: 10.3969/j.issn.1000-8179.20141237
引用本文: 刘新丽, 刘芳芳, 郑屹, 沈蓓蓓, 付丽. 男性乳腺癌临床病理特征及预后分析[J]. 中国肿瘤临床, 2014, 41(23): 1521-1526. DOI: 10.3969/j.issn.1000-8179.20141237
shu
LIU Xinli, LIU Fangfang, ZHENG Yi, SHEN Beibei, FU Li. Clinicopathological features and prognostic factors of male breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(23): 1521-1526. DOI: 10.3969/j.issn.1000-8179.20141237
Citation: LIU Xinli, LIU Fangfang, ZHENG Yi, SHEN Beibei, FU Li. Clinicopathological features and prognostic factors of male breast cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 41(23): 1521-1526. DOI: 10.3969/j.issn.1000-8179.20141237
shu

男性乳腺癌临床病理特征及预后分析

Clinicopathological features and prognostic factors of male breast cancer

    摘要
  • 摘要:
      目的  探讨男性乳腺癌临床病理特征、分子亚型特征及预后的特点。
      方法  收集天津医科大学肿瘤医院135例的男性乳腺癌患者和377例同期诊断为非特殊型浸润性导管癌女性患者临床病理资料, 比较两组预后差异, 对患者年龄、肿瘤大小、淋巴结转移、分期、免疫组织化学指标等因素与预后的关系进行统计学分析。
      结果  与女性乳腺癌相比, 男性乳腺癌好发于乳晕区(P=0.001), 具有较高的雌激素受体、孕激素受体阳性表达率(P < 0.05);男性乳腺癌以Luminal A和Luminal B1型为主, 其所占比例高于女性乳腺癌(P < 0.05);男性乳腺癌5和10年总生存率为81.3%和68.1%、无病生存率为72.3%和50.5%, 显著低于同期诊断的女性乳腺癌5、10年总生存率(91.8%、79.2%)(P=0.001)、无病生存率(82.6%、60.9%)(P=0.003)。单因素生存分析显示肿瘤大小、淋巴结转移、病理学分期、HER-2状态、分子分型是影响男性乳腺癌患者总生存和无病生存预后的因素(P < 0.05), Cox多因素分析显示肿瘤大小和淋巴结转移与男性乳腺癌患者预后有关(P < 0.05)。
      结论  男性乳腺癌较女性乳腺癌预后差, 分子亚型以Luminal A和Luminal B1型为主, 其所占比例高于女性乳腺癌, 表明两者可能具有不同的生物学行为, 早期诊断、早期治疗是改善其预后的关键。

     

    Abstract:
      Objective  To investigate the clinicopathological features, molecular subtypes, and prognosis for male breast cancer (MBC).
      Methods  Clinical data of 135 MBC patients and 377 female breast cancer (FBC) patients with invasive ductal carcinoma not otherwise specified were collected.Differences between the prognostic outcomes of the two groups were compared, and the relationship between clinicopathological characteristics and prognostic significance was analyzed.
      Results  More MBC patients suffered from centrally located tumors, with mammary areola as the predilection site, than FBC patients.The two groups exhibited significant differences (p=0.001).Male patients had a higher ER frequency and positive PR rate than female patients (P<0.05).The most common molecular subtypes of MBC were Luminal A and Luminal B1, and significant differences were identified for molecular subtypes between MBC and FBC patients (P<0.05).The 5-year and 10-year overall survival rates in MBC patients were 81.3% and 68.1%, and disease-free survival rates were 72.3% and 50.5%, respectively.These values were significantly lower than those of FBC patients in the same-period diagnostici.e., 91.8% and 79.2%(P=0.001), and 82.6% and 60.9%(P=0.003), respectively.Kaplan-Meier survival analysis, tumor size, lymph node metastasis, pathological stage, HER-2 status, and molecular subtypes affected the prognosis of MBC patients (P<0.05).In multivariate analysis, the tumor size and lymph node metastasis were associated with a poor prognosis (P<0.05).
      Conclusion  MBC patients experienced a more unfavorable prognosis compared with FBC patients.The most common molecular subtypes of MBC were Luminal A and Luminal B1, which were higher in proportion in MBC patients than in FBC patients.Biological differences contributed to the poor prognosis.Therefore, early diagnosis and treatment are key to improving the prognosis.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回